Deep research
About PT-141 (Bremelanotide)
PT-141, known pharmaceutically as bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist with the chemical sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and a molecular weight of approximately 1025 Da. It is structurally derived from Melanotan II, differing by a single modification: the C-terminal amide (-NH2) of MT-II is replaced with a free carboxylic acid (-OH). This seemingly minor change dramatically shifts the receptor selectivity profile, making PT-141 more selective for MC3R and MC4R (the receptors mediating sexual arousal) while reducing MC1R activity (the receptor responsible for tanning). PT-141 was developed after researchers at the University of Arizona observed unexpected pro-sexual effects during early Melanotan II pigmentation trials.
The mechanism of action of PT-141 is fundamentally different from all other sexual health medications on the market. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) work peripherally by enhancing nitric oxide-mediated vasodilation in genital blood vessels. They address the mechanical, vascular component of erectile function but do not affect desire or arousal. PT-141, by contrast, acts centrally in the brain. It crosses into the CNS and activates MC3R and MC4R receptors in the medial preoptic area and paraventricular nucleus of the hypothalamus, regions that regulate sexual motivation and arousal. This activation triggers downstream dopaminergic and oxytocinergic signaling pathways that increase both subjective desire and physiological arousal responses. Because it targets the neurological origin of sexual response rather than the vascular endpoint, PT-141 is effective in both men and women.
The clinical trial program for PT-141 was extensive. The FDA approved its pharmaceutical formulation, branded as Vyleesi, in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Approval was based on two key Phase 3 trials (RECONNECT studies) enrolling a combined 1,247 premenopausal women. In these trials, PT-141 (1.75 mg subcutaneous, self-administered approximately 45 minutes before anticipated sexual activity) produced a statistically significant increase in desire scores on the Female Sexual Function Index (FSFI) desire domain and a statistically significant decrease in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). Approximately 25% of PT-141-treated women achieved a clinically meaningful response versus 17% on placebo.
In male sexual dysfunction studies, PT-141 demonstrated efficacy in populations that had failed PDE5 inhibitor therapy. In a double-blind, placebo-controlled trial of men with erectile dysfunction who were non-responsive to sildenafil, subcutaneous PT-141 (4 mg) produced clinically meaningful erections (sufficient for intercourse) in 33% of these PDE5 inhibitor non-responders. This is a critical finding because it confirms that PT-141 operates through an independent mechanism. It also showed efficacy in men with ED of psychogenic origin, where the vascular mechanism targeted by PDE5 inhibitors is not the primary issue.
The pharmacokinetics of subcutaneous PT-141 show rapid absorption with a Tmax of approximately 1-1.5 hours. The elimination half-life is approximately 2.7 hours. Bioavailability following subcutaneous injection is approximately 100%. The recommended clinical dose for women (Vyleesi label) is 1.75 mg SC, administered at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than 8 doses per month. PT-141 is metabolized primarily through hydrolysis and renal excretion. It does not interact with the cytochrome P450 system, which minimizes drug-drug interaction risks.
For reconstitution and storage of the lyophilized research form, store unreconstituted vials at -20 degrees C. Reconstitute with bacteriostatic water. Once reconstituted, store at 2-8 degrees C and use within 4 weeks. The lyophilized powder is stable for 24+ months at -20 degrees C. Protect from light. The peptide is stable at physiological pH (6.5-7.5).
The most commonly reported adverse effects in the RECONNECT Phase 3 trials were transient nausea (occurring in approximately 40% of subjects, typically mild and diminishing with subsequent doses), flushing (20%), injection site reactions (13%), and headache (11%). Nausea was the primary reason for discontinuation (5.6% vs 0.4% placebo). A transient increase in blood pressure of 2-3 mmHg systolic and 1-2 mmHg diastolic was observed, resolving within 12 hours. Unlike PDE5 inhibitors, PT-141 does not carry cardiovascular contraindications related to nitrate use, making it an option for patients who cannot use sildenafil-class drugs. The FDA label recommends against use in patients with uncontrolled hypertension or cardiovascular disease as a precaution.
